Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study

Bibliography

• Cheetham TC, Wagner RA, Chiu G, A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006;55:442-8
   PubMed Web of Science ®Google Scholar
• Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26:599-606
   PubMed Web of Science ®Google Scholar
• Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a women where fetus has been exposed to isotretinoin? Arch Dermatol 2007;143:1187-8
   PubMed Web of Science ®Google Scholar
• Lammer E, Chen D, Hoar R, Retinoic acid embryopathy. NEJM 1985;313:837-41
   PubMed Web of Science ®Google Scholar
• Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;11:1978-83
   Google Scholar
• Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Isotretinoin/human_referral_000086.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac0580024e9a [Last accessed on 01 February 2012]
   Google Scholar
• Crijns I, Straus S, Luteijn M, Implementation of the harmonised EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies. Drug Saf 2012;35:27-32
   PubMed Web of Science ®Google Scholar
• Shin J, Cheetham T, Wong L, The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health system. J Am Acad Dermatol 2011;65:1117-25
   PubMed Web of Science ®Google Scholar
• Autret-Leca E, Kreft-Jais C, Elefant E, Isotretinoin exposure during pregnancy – Assessment of spontaneous reports in France. Drug Saf 2010;33:659-65
   PubMed Web of Science ®Google Scholar
• ,·Schaefer C, Meister RWeber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010;281:221-7
   PubMed Web of Science ®Google Scholar
• Teichert M, Visser L, Dufour M, Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme A retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf 2010;33:315-26
   PubMed Web of Science ®Google Scholar
• Crijns H, van Rein N, Gispen-de Wied C, Prescriptive Contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Pharmacoepidemiol Drug Saf 2012;21(10):1060-6
   PubMed Web of Science ®Google Scholar
• Arriegas M, Pégo A, Lemos M, Clérigo I. Isotretinoin – PPP compliance [abstract]. Drug Saf 2009;10:984
   Google Scholar
• Jeanmougin M, Beaulieu P, Doutre M, Jaramillo C. Aide au bon usage de l'isotrétinoïn en pratique libérale: observatoire prospectif de 1263 patients acnéiques. Ann Dermatol Venereol 2009;136:54-61
   PubMedGoogle Scholar
• Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. Trans Am Ophthalmol Soc 2009;107:205-13
   PubMedGoogle Scholar
• Handler SM, Shierts BH, Perera S, Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study. Consult Pharm 2008;23:387-95
   PubMedGoogle Scholar
• Metcalfe PD, Elyas R. Foreskin management – Survey of Canadian pediatric urologists. Can Fam Physician 2010;56:e290-5
   PubMed Web of Science ®Google Scholar
• Wilbur K. Resident physician and hospital pharmacist familiarity with patient discharge medication costs. Pharm World Sci 2009;31:195-201
   PubMed Web of Science ®Google Scholar
• Van Gelder M, Bretveld R, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am J Epidemiol 2010;172:1292-8
   PubMed Web of Science ®Google Scholar
• Boucher N, Beaulac-Baillargeon L. Pregnancy Prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician 2006;52:339-42
   Google Scholar
• Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007;147:370-6
   PubMed Web of Science ®Google Scholar
• Bérard A, Azoulay L, Koren G, Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007;63:196-205
   PubMed Web of Science ®Google Scholar
• Crijns H, Straus S, Gispen-de Wied C, de Jong-van den Berg L. Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review. Br J Dermatol 2011;164:238-44
   PubMed Web of Science ®Google Scholar
• Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies. Arch Dermatol 2005;141:563-9
   PubMed Web of Science ®Google Scholar
• AlGhamdi K, Khurram H, Asiri Y, Mandil A. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential. Int J Dermatol 2011;50:1094-8
   PubMed Web of Science ®Google Scholar